A new blood test developed by Guardant Health could become another screening option for colorectal cancer if approved by the FDA. The test detects 83% of people with colorectal cancer and could help improve early detection. However, it will not replace colonoscopies as the next step if the test is positive.
Key Points
Guardant Health developed a blood test for colorectal cancer screening
Test detects circulating tumor DNA in the bloodstream
Could reach more people for screening
Colonoscopy still necessary if blood test is positive
Pros
Blood test could detect 83% of people with colorectal cancer
Less invasive than colonoscopy
Could improve early detection of colorectal cancer
Cons
Will not replace colonoscopies for further evaluation
May not be as effective in detecting precancerous lesions compared to colonoscopy